MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
Status:
Terminated
Trial end date:
2020-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with
acceptable safety profile and that can be used in patients affected by CD205-positive solid
tumors and Non-Hodgkin Lymphoma